Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pharmacokinetics of letrozole: association with key body mass metrics.

International journal of clinical pharmacology and therapeutics - 1 Aug 2012

Jin Seok-Joon, Jung Jin Ah, Cho Sang-Heon, Kim Un-Jib, Choe Sangmin, Ghim Jong-Lyul, Noh Yook-Hwan, Park Hyun-Jung, Kim Jung-Chul, Jung Jin-A, Lim Hyeong-Seok, Bae Kyun-Seop

Abstract excerpt

PURPOSE: To characterize the pharmacokinetics (PK) of letrozole by noncompartmental and mixed effect modeling analysis with the exploration of effect of body compositions on the PK. METHODS: The PK data of 52 normal healthy male subjects with intensive PK sampling from two separate studies were included in this analysis. Subjects were given a single oral administration of 2.5 mg letrozole (Femara®), an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase Inhibitors
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Body Composition

Share to Cytochrome P-450 CYP2A6

Share to Cytochrome P-450 CYP3A

Share to Models, Biological

Share to Nitriles

Share to Triazoles

Source

Identifiers

PMID: 22735458
DOI: 10.5414/CP201709

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pharmacokinetics of letrozole: association with key body mass metrics.PMID 22735458Read ↗

Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.Semantic proximity Read ↗

Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.Semantic proximity Read ↗

Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.Semantic proximity Read ↗

Population pharmacokinetic modeling of tamoxifen and its active metabolite endoxifen in healthy volunteers of African ancestry genotyped for CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5.Semantic proximity Read ↗

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.Semantic proximity Read ↗

Anastrozole.Semantic proximity Read ↗

Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.Semantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balanceSemantic proximity Read ↗

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patientsSemantic proximity Read ↗

A tutorial on physiologically based pharmacokinetic approaches in lactation researchSemantic proximity Read ↗

Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients.Semantic proximity Read ↗

Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.